News
Public · Published
Canaccord Genuity maintains Ultragenyx Pharmaceutical at Buy, lowers price target to $34 from $39
Canaccord Genuity kept its Buy rating on Ultragenyx Pharmaceutical but cut its price target to $34 from $39, a 12.8% decrease. The article says the new target implies 98.1% upside from the November 4 closing price of $17.16.
Published:
Updated:
What happened
Canaccord Genuity kept its Buy rating on Ultragenyx Pharmaceutical but cut its price target to $34 from $39, a 12.8% decrease. The article says the new target implies 98.1% upside from the November 4 closing price of $17.16.
Confirmed
Global impact / market context
The lower target signals that Canaccord sees less potential value than before, even while retaining its Buy rating. A price target is an analyst’s estimate, not a promised share price; the article provides no company operating news to explain the change.
Analyst inference
The target remains above the November 4 close, but the five other recent analyst targets listed range from $17 to $22. That contrast shows Canaccord’s estimate is an outlier in this small set, rather than a shared view among the listed analysts.
Analyst inference
What to watch
- Check whether Canaccord publishes further changes to its rating or target, since the article records a lower estimate but gives no reason for the revision. Analyst inference
- Compare future analyst targets with the listed $17–$22 range; a widening or narrowing gap would show whether views are becoming more aligned. Analyst inference
- Look for company updates on revenue, costs, or cash available that could provide operating evidence behind later changes in analysts’ estimates. Analyst inference
Evidence
- Original source link unavailable